FDA Approvals Roundup: Cabenuva, Lupkynis, Verquvo

A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA).

New approvals
Cabenuva approved as first extended-release, injectable regimen for adults with HIV
ViiV Healthcare’s Cabenuva (cabotegravir and rilpivirine injection) has been approved as a long-acting, once-monthly regimen for patients HIV-1 infection.